Mizuho Securities Stick to Their Hold Rating for SAGE Therapeutics


Mizuho Securities analyst Vamil Divan maintained a Hold rating on SAGE Therapeutics (NASDAQ:SAGE) on Friday, setting a price target of $53, which is approximately 2.30% below the present share price of $54.25.

Divan expects SAGE Therapeutics to post earnings per share (EPS) of -$2.44 for the third quarter of 2020.

The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in SAGE Therapeutics, with an average price target of $68.36.
The analysts price targets range from a high of $87 to a low of $40.

In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $2.29 million and a net profit of -$131.62 million. The company’s market cap is $2.82 billion.

According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.3% and a 40.51% success rate.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.


About Author

Leave A Reply